<DOC>
	<DOCNO>NCT02973659</DOCNO>
	<brief_summary>Primary focal hyperhidrosis interferes daily activity . Limited efficacy , cost , side effect complication issue concern current therapeutic modality . In study invetigators aim evaluate efficacy topical oxybutynin 10 % gel treat primary focal hyperhidrosis . 60 patient primary focal hyperhidrosis recruit . Topical oxybutynin 10 % gel assign right left axilla , palm sole placebo compound contralateral side total 30 day . The Hyperhidrosis Disease Severity Scale ( HDSS ) Dermatology Life Quality Index ( DLQI ) questionnaires administer treatment , 2 noninvolved blind physician score result use starch-iodine test . The participant grade sweat reduction side rat satisfaction .</brief_summary>
	<brief_title>The Use Topical Oxybutynin 10 % Treating Primary Focal Hyperhidrosis-axillary , Palmar Plantar .</brief_title>
	<detailed_description>This study perform Tel Aviv Medical Center . Written inform consent obtain 60 participant prior enter study . patient primary focal hyperhidrosis ( palmar hyperhidrosis , axillary hyperhidrosis , plantar hyperhidrosis ) receive topical oral anticholinergic , iontophoresis treatment botulinum toxin injection 6 month prior study entry undergone sympathectomy recruit . Demographic data , include gender , age medical history collect enrollment study , follow patient exclude : pregnant lactate woman , individual condition may cause secondary hyperhidrosis , individual history eczema , seborrhea , psoriasis , glaucoma , micturition disorder , gastric retention , myasthenia gravis , angioedema , Sjögren 's syndrome , Sicca syndrome , candidate older 60 year younger 18 year . The study follow prospective , randomize , double blind , placebo-controlled design . Each participant give pair test jar ( designate `` 'gel A '' ' `` 'gel B '' ' ) . The investigator use designate software randomize jar ( either A B ) contain 10 % oxybutynin gel placebo aqueous gel . The two jar identical shape , size weight , well color , odor consistency . The patient instruct apply 1 cm gel A B clean , dry intact skin one sweat area ( right left palm , sol axillae ) twice daily 30 day . In addition , participant instruct avoid contact gel eye , nose , mouth , wash area 4 hour post-application . The participant also instruct use concomitant topical systemic medication entire treatment period . Each jar weigh digital scale treatment initiation 30th day treatment . The participant interview twice , first time screen initial application follow completion 30th day treatment . The participant ask rate severity condition use hyperhidrosis disease severity scale score 3 4 indicates severe hyperhidrosis score 1 2 indicates mild moderate hyperhidrosis . The therapeutic result consider `` excellent '' `` good '' patient indicate reduction 2 1 point , respectively , HDSS score . In addition , quality life assess modify Dermatology Life Quality Index . The maximum score 30 , 0 indicate negligible effect disorder patient 's quality life 30 indicate significant impact . A change 0-1 point mDLQI score interpret reflect effect patient 's life , change 2-5 point small effect , 6-10 point moderate effect , 11-20 point significant modification , 21-30 point significant impact possible . At end treatment , patient complete questionnaire evaluate following : 1 . Sweat reduction treat control sweat area ( 0 = change , 1 = poor ( limited improvement patient much aware sweat ) , 2 = fair ( marked improvement , noticeable sweat stressful condition , 3 = good ( marked improvement minimal sweat stressful condition ) , 4 = excellent improvement , cessation sweat ) 2 . Global patient satisfaction ( 0 = dissatisfy , 1 = partially satisfy , 2 = satisfy , 3 = highly satisfy ) . 3 . Side effect : dry mouth , headache , dizziness , urine retention , constipation application site reaction ( pruritus dermatitis ) . All patient undergo Minor iodine-starch test . The tested area photograph standard condition use Galaxy Camera ( 3G ) EK-GC100 photography system . Photographs take 30 day treatment independently assess two dermatologist unaware study design . All pair photograph grade 0 = change , 1 = minor change &lt; 25 % , 2 = moderate change 25-50 % , 3 = major change 50-75 % , 4 = absence near absence sweating . Both study control gel compound Israeli compound pharmacy . Continuous variable feed tabular format mean ± standard error compare use Wilcoxon pair test . Categorical variable test use Fisher exact test . Correlation raters evaluate use Spearman 's correlation . All analysis carry use SPSS 23.0.2 .</detailed_description>
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>healthy individual primary hyperhidrosis ( axillary , palmar , plantar ) diagnose accord recommend criteria4 : focal , visible excessive sweating least 6 month duration without apparent cause , least two follow characteristic : bilateral symmetric , impair daily activity , one episode per week , onset age 25 year , positive family history , cessation sleep . give write informed patient consent participation study know history condition may cause secondary hyperhidrosis eczema , seborrhea , psoriasis active lesion treatment site treatment hyperhidrosis within 4 week Any medical condition aggravate anticholinergic medication : glaucoma , micturition disorder , gastric retention , myasthenia gravis , angioedema , know history Sjögren 's syndrome Sicca syndrome iodine allergy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>